Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Saturday, December 14th, 2013
Medicalxpress: December 8, 2013
Diabetes was associated with an increased risk for developing a type of liver cancer called hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.
People with diabetes have a two- to threefold higher risk for hepatocellular carcinomacompared with those without diabetes,” said V. Wendy Setiawan, Ph.D., assistant professor in the Department of Preventive Medicine at Keck School of Medicine of the University of Southern California. “We also found that the interethnic differences in the prevalence of diabetes were consistent with the pattern of hepatocellular carcinoma incidence observed across ethnicities: Ethnic groups with a high prevalence of diabetes also have high hepatocellular carcinoma rates, and those with a lower prevalence of diabetes have lower hepatocellular carcinoma rates.” Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Saturday, December 14th, 2013
Biomedcentral: 10 December 2013
Lifestyle intervention in type 2 diabetes mellitus (T2DM) is effective but needs a special local setting and is costly. Therefore, in a randomized-controlled trial we tested the hypothesis that the autonomous use of the interactive exercise game Wii Fit Plus over a period of 12?weeks improves metabolic control, with HbA1c reduction as the primary outcome, and weight loss, reduction of cardiometabolic risk factors, physical activity and quality of life (secondary outcomes) in T2DM patients. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Saturday, December 14th, 2013
Diabetes Care: December 6, 2013
Objective The goal was to develop a new index of insulin sensitivity in patients with type 1 diabetes estimated from continuous glucose monitoring (CGM) and subcutaneous insulin delivery data under carefully controlled conditions.
Research Design & Methods The data base consists of 12 subjects with type 1 diabetes, studied during breakfast, lunch and dinner, in a clinical research unit, wearing both subcutaneous insulin pump and CGM. Frequent blood samples were drawn for measurements of plasma glucose and insulin concentrations in order to estimate insulin sensitivity with the oral minimal model (SIMM). The new index of insulin sensitivity (SISP) was calculated with a simple algebraic formula, for each meal, using only CGM and insulin pump data and compared with SIMM. Read more
Posted by Diabetes South Texas Staff
Clinical Trial News
Saturday, December 14th, 2013
Diabetes Care: December 2, 2013
Objective To determine the occurrence of extremely low HDL-C among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD).
Research Design and Methods The ACCORD Lipid Trial was a randomized double blind placebo controlled study conducted in patients with type 2 diabetes at 77 clinical centers across the United States and Canada in a 5,518 patient sub-set of the larger 10,251 ACCORD Glycemia Trial. Patients were enrolled from January 11, 2001 until October 29, 2005 and followed until end of study visits between March 1 and June 30, 2009. Follow-up in ACCORD Lipid was 4 to 8 years (mean 4.7 years). Patients were treated with blinded fenofibrate or placebo on a background of simvastatin therapy. The main outcome measures for these descriptive, post hoc analyses was the occurrence of extremely low HDL-C (defined as < 25 mg/dl [0.647 mmol/L]) during the trial. Read more
Posted by Diabetes South Texas Staff
Clinical Trial News
Saturday, December 14th, 2013
Diabetes Care: December 2, 2013
Objective We previously reported that two years of co-stimulation modulation with abatacept slowed decline of beta-cell function in recent-onset type 1 diabetes mellitus (T1DM). Subsequently, abatacept was discontinued, and subjects followed to determine whether there was persistence of effect.
Research Design and Methods In 112 subjects (ages 6-36) with T1DM, 77 received abatacept and 35 received placebo infusions intravenously for 27 infusions over two years. The primary outcome – baseline-adjusted geometric mean 2-hour area under the curve (AUC) serum C-peptide during a mixed meal tolerance test (MMTT) at two years – showed higher C-peptide with abatacept versus placebo. Subjects were followed an additional year, off treatment, with MMTTs performed at 30 and 36 months. Read More
Posted by Diabetes South Texas Staff
News
Saturday, December 14th, 2013
Cambridge: 10 December 2013
Introduction Diabetes mellitus, although a chronic disease, also can cause acute, sudden symptoms requiring emergency intervention. In these cases, Emergency Medical Dispatchers (EMDs) must identify true diabetic complaints in order to determine the correct care. In 911 systems utilizing the Medical Priority Dispatch System (MPDS), International Academies of Emergency Dispatch-certified EMDs determine a patient’s chief complaint by matching the caller’s response to an initial pre-scripted question to one of 37 possible chief complaints protocols. The ability of EMDs to identify true diabetic-triggered events reported through 911 has not been studied.
Objective The primary objective of this study was to determine the percentage of EMD-recorded patient cases (using the Diabetic Problems protocol in the MPDS) that were confirmed by either attending paramedics or the hospital as experiencing a diabetic-triggered event. Read More
Posted by Diabetes South Texas Staff
News
Saturday, December 14th, 2013
JAMA: December 09, 2013
Importance In the coming decades, the population of older adults with type 2 diabetes mellitus is expected to grow substantially. Understanding the clinical course of diabetes in this population is critical for establishing evidence-based clinical practice recommendations, identifying research priorities, allocating resources, and setting health care policies.
Objective To contrast the rates of diabetes complications and mortality across age and diabetes duration categories.
Design, Setting, and Participants This cohort study (2004-2010) included 72 310 older (≥60 years) patients with type 2 diabetes enrolled in a large, integrated health care delivery system. Incidence densities (events per 1000 person-years) were calculated for each age category (60-69, 70-79, and ≥80 years) and duration of diabetes (shorter [0-9 years] vs longer [≥10 years]).Read More
